Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This pilot project is an open-label trial that will offer psilocybin in a group format to assess the feasibility of offering psilocybin therapy in a group setting with a decreased therapist to subject ratio. Study intervention will involve a group of six patients with one therapist per subject for a 1:1 ratio, thus significantly reducing the total number of therapist hours per subject compared to standard individual therapy protocols. Two groups of six will be treated on this trial. After the enrollment and treatment of the first group of six patients, accrual will be placed on hold to ensure subject safety. If stopping rules are not met (Section 11), the next group of six patients will be enrolled and treated on study. The study intervention will include a total of seven group therapy sessions including three 2-hour preparatory sessions, one 8-hour psilocybin session, and one two-hour integration session. The group therapy sessions will occur on a weekly basis, followed one week later by the psilocybin session. The first integration group session will occur 1-2 days following the psilocybin session.
Description: assess the safety of psilocybin in patients with a cancer diagnosis or hematologic malignancy.
Measure: Number of adverse events (AEs) and serious adverse events (SAEs) characterized by severity Time: 8 monthsDescription: assess the safety of psilocybin in patients with a cancer diagnosis or hematologic malignancy.
Measure: Number of adverse events (AEs) and serious adverse events (SAEs) characterized by duration Time: 8 monthsDescription: assess the safety of psilocybin in patients with a cancer diagnosis or hematologic malignancy.
Measure: Number of adverse events (AEs) and serious adverse events (SAEs) characterized by relationship to study treatment. Time: 8 monthsDescription: assess the safety of psilocybin in patients with a cancer diagnosis or hematologic malignancy.
Measure: Number of adverse events (AEs) and serious adverse events (SAEs) characterized by seriousness Time: 8 monthsDescription: assess the safety of psilocybin in patients with a cancer diagnosis or hematologic malignancy.
Measure: Number of adverse events (AEs) and serious adverse events (SAEs) characterized by type Time: 8 monthsDescription: assess the feasibility to recruit patients with a cancer diagnosis or hematologic malignancy
Measure: recruitment of patients with cancer diagnosis or hematologic malignancy Time: 18 monthsDescription: assess the feasibility to enroll patients with a cancer diagnosis or hematologic malignancy
Measure: Enrollment of patients with a cancer diagnosis or hematologic malignancy Time: 18 monthsDescription: assess the feasibility to consent patients with a cancer diagnosis or hematologic malignancy
Measure: Consent of patients with a cancer diagnosis or hematologic malignancy Time: 18 monthsDescription: assess the tolerability of psilocybin in patients with a cancer diagnosis or
Measure: Number of adverse events (AEs) and serious adverse events (SAEs) characterized by severity Time: 8 monthsDescription: assess the tolerability of psilocybin in patients with a cancer diagnosis or
Measure: Number of adverse events (AEs) and serious adverse events (SAEs) characterized by relationship to study treatment. Time: 8 monthsDescription: assess the tolerability of psilocybin in patients with a cancer diagnosis or
Measure: Number of adverse events (AEs) and serious adverse events (SAEs) characterized by duration. Time: 8 monthsDescription: assess the tolerability of psilocybin in patients with a cancer diagnosis or
Measure: Number of adverse events (AEs) and serious adverse events (SAEs) characterized by seriousness. Time: 8 monthsDescription: assess the tolerability of psilocybin in patients with a cancer diagnosis or
Measure: Number of adverse events (AEs) and serious adverse events (SAEs) characterized by type. Time: 8 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports